Search results
Results from the WOW.Com Content Network
The FDA's decision is a win for Lilly, the drug's manufacturer, according to the Associated Press, prices and ways to access drugs like Zepbound and Mounjaro could be affected as a result of the move.
Diabetes treatment Mounjaro has been on the health regulator's shortage list since late 2022, while weight-loss drug Zepbound was added in April as demand far outstripped supply. The limited ...
A news release from Eli Lilly in June 2024 outlines some concerns surrounding compounded versions of tirzepatide (the active ingredient in Mounjaro and Zepbound), some of which contained bacteria ...
Lilly's drug, tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management, will cease to be in shortage "very soon," CEO David Ricks said in an interview with Bloomberg in Paris.
The popularity of GLP-1 weight loss drugs has soared, which had created a shortage among many of the drugs, including Eli Lilly's (NYSE: LLY) popular Mounjaro and Zepbound. However, the U.S. Food ...
(Reuters) -All doses of Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are now available, the U.S. Food and Drug Administration's updated shortage list showed on Friday. However ...
Eli Lilly and Co. on Thursday warned against use of its popular diabetes and weight loss drugs Mounjaro and Zepbound for “cosmetic” reasons. The news comes as rampant demand for the reputed ...
Mounjaro had been on the FDA's list of drugs in short supply since late 2022, while Zepbound was added in April. Compounding facilities create medicines by combining, mixing or altering drug ...